US Patent Issued to The Trustees of the University of Pennsylvania on Oct. 21 for "Fully-human T-cell receptor specific for the 369-377 epitope derived from the Her2/neu (ERBB2) receptor protein" (Pennsylvania Inventor)

ALEXANDRIA, Va., Oct. 28 -- United States Patent no. 12,448,431, issued on Oct. 21, was assigned to The Trustees of the University of Pennsylvania (Philadelphia).

"Fully-human T-cell receptor specific for the 369-377 epitope derived from the Her2/neu (ERBB2) receptor protein" was invented by Daniel J. Powell Jr. (Bala Cynwyd, Pa.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to compositions and methods for treating HER2/Neu (ERBB2) expressing cancer cells. In some embodiments, the invention includes an isolated T cell receptor (TCR) having high affinity for and that specifically binds ERBB2369-377 epitope on a target cell. Other embodiments include a T cell or a population of T...